Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis.

Funakoshi T, Shimada YJ.

Acta Oncol. 2013 May;52(4):691-702. doi: 10.3109/0284186X.2012.752579. Epub 2013 Jan 3. Review.

PMID:
23282114
2.

Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.

Funakoshi T, Latif A, Galsky MD.

Cancer Treat Rev. 2013 Nov;39(7):818-30. doi: 10.1016/j.ctrv.2013.01.004. Epub 2013 Feb 28. Review.

PMID:
23455076
3.

Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.

Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK.

J Clin Oncol. 2011 Sep 1;29(25):3450-6. doi: 10.1200/JCO.2010.34.4309. Epub 2011 Aug 1.

PMID:
21810682
4.

Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.

Chu D, Lacouture ME, Weiner E, Wu S.

Clin Genitourin Cancer. 2009 Jan;7(1):11-9. doi: 10.3816/CGC.2009.n.002.

PMID:
19213662
5.

Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.

Abdel-Rahman O, Fouad M.

Crit Rev Oncol Hematol. 2014 Dec;92(3):194-207. doi: 10.1016/j.critrevonc.2014.06.003. Epub 2014 Jul 1. Review.

PMID:
25028151
6.

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.

Zhu X, Stergiopoulos K, Wu S.

Acta Oncol. 2009;48(1):9-17. doi: 10.1080/02841860802314720. Review.

PMID:
18752081
7.

Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis.

Abdel-Rahman O, Fouad M.

Expert Rev Anticancer Ther. 2014 Sep;14(9):1063-73. doi: 10.1586/14737140.2014.929501. Epub 2014 Jun 13. Review.

PMID:
24927771
8.

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

Je Y, Schutz FA, Choueiri TK.

Lancet Oncol. 2009 Oct;10(10):967-74. doi: 10.1016/S1470-2045(09)70222-0. Epub 2009 Sep 18. Review.

PMID:
19767240
9.

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J.

J Clin Oncol. 2010 May 1;28(13):2280-5. doi: 10.1200/JCO.2009.27.2757. Epub 2010 Mar 29. Review.

PMID:
20351323
10.

Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?

Tassi R, Baldazzi V, Lapini A, Carini M, Mazzanti R.

Clin Genitourin Cancer. 2015 Apr;13(2):e101-5. doi: 10.1016/j.clgc.2014.08.009. Epub 2014 Sep 22.

PMID:
25450040
11.

Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.

Santoni M, Conti A, De Giorgi U, Iacovelli R, Pantano F, Burattini L, Muzzonigro G, Berardi R, Santini D, Cascinu S.

Int J Cancer. 2014 Aug 15;135(4):763-73. doi: 10.1002/ijc.28544. Epub 2013 Nov 18. Review.

12.

Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.

Feldt S, Schüssel K, Quinzler R, Franzmann A, Czeche S, Ludwig WD, Schulz M.

Eur J Cancer. 2012 May;48(7):974-81. doi: 10.1016/j.ejca.2012.01.036. Epub 2012 Feb 28.

PMID:
22382202
13.

Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.

Santoni M, Conti A, Massari F, Arnaldi G, Iacovelli R, Rizzo M, De Giorgi U, Trementino L, Procopio G, Tortora G, Cascinu S.

Int J Cancer. 2015 Jan 1;136(1):1-10. doi: 10.1002/ijc.28715. Epub 2014 Feb 7. Review.

14.
15.

Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis.

Abdel-Rahman O, Fouad M.

Expert Rev Anticancer Ther. 2015 Jan;15(1):129-41. doi: 10.1586/14737140.2015.985660. Epub 2014 Dec 8. Review.

PMID:
25482593
16.

[Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].

Fuertes Zamorano N, De Miguel Novoa MP, Molino González A, Díaz Pérez JÁ, Rojas-Marcos PM, Montañez Zorrilla MC.

Endocrinol Nutr. 2010 Dec;57(10):486-91. doi: 10.1016/j.endonu.2010.06.002. Epub 2010 Aug 10. Spanish.

PMID:
20702151
17.

Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature.

Abdel-Rahman O, Fouad M.

Crit Rev Oncol Hematol. 2015 May;94(2):238-50. doi: 10.1016/j.critrevonc.2015.01.006. Epub 2015 Jan 19. Review.

PMID:
25638704
18.

Thyroid dysfunction in patients treated with sunitinib or sorafenib.

Clemons J, Gao D, Naam M, Breaker K, Garfield D, Flaig TW.

Clin Genitourin Cancer. 2012 Dec;10(4):225-31. doi: 10.1016/j.clgc.2012.08.002. Epub 2012 Sep 25.

19.

Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.

Carlisle B, Demko N, Freeman G, Hakala A, MacKinnon N, Ramsay T, Hey S, London AJ, Kimmelman J.

J Natl Cancer Inst. 2015 Nov 7;108(1). pii: djv292. doi: 10.1093/jnci/djv292. Print 2016 Jan. Review.

PMID:
26547927
20.

Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.

Kitajima K, Takahashi S, Maeda T, Yoshikawa T, Ohno Y, Fujii M, Miyake H, Fujisawa M, Sugimura K.

Eur J Radiol. 2012 Sep;81(9):2060-5. doi: 10.1016/j.ejrad.2011.06.035. Epub 2011 Jul 2.

PMID:
21724350

Supplemental Content

Support Center